Cambridge, MA — February 11, 2026 — Leads & Copy — Vyome Holdings, Inc. (NASDAQ: HIND) has filed for Orphan Drug Status for VT-1953, its lead clinical program, the company announced today.
The biopharmaceutical company, which focuses on developing therapies for immuno-inflammatory and rare conditions, anticipates that an orphan drug designation would provide key benefits. These include seven years of U.S. market exclusivity, up to 25% tax credits on U.S. clinical trials, exemption from FDA Prescription Drug User Fee Act (PDUFA) fees, and specialized regulatory support.
VT-1953 is being developed to treat symptoms of malignant fungating wounds (MFW), a debilitating medical condition affecting approximately 10% of advanced cancer patients, causing severe malodor, pain, and emotional distress. Currently, no FDA-approved therapies exist for this condition.
Vyome recently reported positive Phase 2 clinical results, where VT-1953 met key primary and secondary clinical endpoints. An independent assessment by Destum Partners estimates the total addressable pharmacologic market in the U.S. for MFW at approximately $2.2 billion. This assessment projects the U.S. asset value at $455 million, based on a risk-adjusted net present value (rNPV) methodology, following positive Phase 2 data. The valuation is projected to approach $1 billion after successful Phase 3 completion, according to Destum Partners.
“Our responsibility is to maximize shareholder value, which includes advancing the Company’s most important assets and also ensuring the potential profits are treated correctly,” said Krishna Gupta, Chairman of the Board.
Gupta said VT-1953 targets a serious condition with no approved therapies, and the roadmap reflects a deliberate and responsible approach.
Vyome believes that VT-1953 is central to its value proposition:
- Independent third-party assessment estimates a current VT-1953 valuation of approximately $455 million.
- The same analyst independently illustrated the VT-1953 value at $1 billion post-Phase 3, supported by an estimated $2.2 billion U.S. total addressable market.
- Submission for orphan drug designation to the FDA is in line with improving cost and regulatory process efficiency.
- FDA interaction on the Phase 3 protocol is planned in Q2 of 2026.
- All contract research organizations (“CRO”) necessary to complete the Phase 3 are currently engaged with clear cost expectations.
- The Company has required capital on hand to reach critical interim results from the Phase 3 efficacy study, expected in mid-2027.
“As we have repeatedly stated since going public in August, we have been hyper-focused on capital discipline and dilution, well-planned key executional milestones, maintaining a clean capital structure while aligning long-term clinical execution with shareholder interests. We have put an experienced and dedicated team in place in order to deliver the interim results of the Phase 3 study in mid-2027 with the required capital in place,” stated Venkat Nelabhotla, CEO of Vyome.
Vyome is building a platform spanning the US-India innovation corridor, based in Cambridge, MA, with an immediate focus on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying science and its unique positioning, Vyome seeks to deliver value to shareholders while upholding quality and safety standards.
Source: Vyome Holdings, Inc.
